Publication Date: 2022-11-29
Practice Area: Patent Litigation
Industry: Pharmaceuticals
Court: U.S. District Court of Delaware
Judge: District Judge Andrews
Attorneys: For plaintiff: Daniel M. Silver, Alexandra M. Joyce, McCarter & English, LLP, Wilmington, DE; Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas, Venable LLP, New York, NY for plaintiff.
for defendant: Dominick T. Gattuso, Heyman Enerio Gattuso & Hirzel LLP, Wilmington, DE; Scott A. Cunning II, Elizabeth M. Crompton, Parker Poe Adams & Bernstein, LLP, Washington, DC; C. Kyle Musgrove, Parker Poe Adams & Bernstein, LLP, Charlotte, NC for defendant.
Case Number: 20-md-2930-RGA
Court dismissed infringement claims and counterclaims of non-infringement after defendant converted its Paragraph IV certification to a 21 U.S.C. §355(j)(2)(A)(viii) statement averring the non-infringement of its ANDA product.